Dystrophy Clinical Trials

Find clinical trials for Dystrophy. Search for Dystrophy clinical trials in different cities and states across the United States.

Filter

Filter results

Results: 126

Feasibility of the BrainGate2 Neural Interface System in Persons With Tetraplegia

Recruiting

Sponsor:

Leigh R. Hochberg, MD, PhD.

Location:

Stanford, Boston

Code:

NCT05724173

Conditions

Anarthria

Dysarthria

Tetraplegia

Spinal Cord Injuries

Amyotrophic Lateral Sclerosis

Eligibility Criteria

Sex: All

Age: 18 - 70+

Healthy Volunteers: Not accepted

Interventions

BrainGate Neural Interface System

Investigating Exercise in Myotonic Dystrophy Type 2 (DM2)

Recruiting

Sponsor:

Massachusetts General Hospital

Location:

Boston

Code:

NCT06716931

Conditions

Myotonic Dystrophy 2

Eligibility Criteria

Sex: All

Age: 18 - 70

Healthy Volunteers: Not accepted

Interventions

Exercise

Ph2 Open-label Study of AOC 1044 in Duchenne Muscular Dystrophy Participants with Mutations Amenable to Exon44 Skipping

Recruiting

PHASE2

Sponsor:

Avidity Biosciences, Inc.

Location:

Little Rock, La Jolla, Sacramento, San Carlosshow 6 more

Code:

NCT06244082

Conditions

DMD

Duchenne Muscular Dystrophy

Duchenne

Exon 44

Eligibility Criteria

Sex: Male

Age: 7 - 27

Healthy Volunteers: Not accepted

Interventions

AOC 1044

BS01 in Patients With Retinitis Pigmentosa

Recruiting

PHASE1

PHASE2

Sponsor:

Bionic Sight LLC

Location:

New York

Code:

NCT04278131

Conditions

Retinitis Pigmentosa

Eligibility Criteria

Sex: All

Age: 18+

Healthy Volunteers: Not accepted

Interventions

BS01

Phase 2 Tolerability and Effects of ALK-001 on Stargardt Disease

Recruiting

PHASE2

Sponsor:

Alkeus Pharmaceuticals, Inc.

Location:

Los Angeles, Gainesville, Miami, Baltimoreshow 4 more

Code:

NCT02402660

Conditions

Stargardt Disease

Stargardt Macular Degeneration

Stargardt Macular Dystrophy

Autosomal Recessive Stargardt Disease 1 (ABCA4-related)

Eligibility Criteria

Sex: All

Age: 8 - 70

Healthy Volunteers: Not accepted

Interventions

ALK-001

Placebo

SAD of IVT VP-001 in PRPF31 Mutation-Associated Retinal Dystrophy Subjects

Recruiting

PHASE1

Sponsor:

PYC Therapeutics

Location:

Jacksonville, Miami, Ann Arbor, Portlandshow 2 more

Code:

NCT05902962

Conditions

Retinal Dystrophy

PRPF31 Mutationassociated Retinal Dystrophy

RP11

Eligibility Criteria

Sex: All

Age: 18+

Healthy Volunteers: Not accepted

Interventions

VP-001

Motor Outcomes to Validate Evaluations in FSHD (MOVE FSHD)

Recruiting

Sponsor:

University of Kansas Medical Center

Location:

Los Angeles, Stanford, Aurora, Gainesvilleshow 12 more

Code:

NCT04635891

Conditions

FSHD

Eligibility Criteria

Sex: All

Age: 0 - 70+

Healthy Volunteers: Not accepted

LGMD R1 Natural History Study

Recruiting

Sponsor:

Virginia Commonwealth University

Location:

Orange, Aurora, Gainesville, Shipshewanashow 6 more

Code:

NCT05618080

Conditions

Calpain-3 Deficiency Limb Girdle Muscular Dystrophy Type 2A

Limb Girdle Muscular Dystrophy

Limb Girdle Muscular Dystrophy Type R1

LGMD2A

Eligibility Criteria

Sex: All

Age: 12 - 50

Healthy Volunteers: Not accepted

Defining Endpoints in Becker Muscular Dystrophy

Recruiting

Sponsor:

Virginia Commonwealth University

Location:

Orange, Aurora, Iowa City, Kansas Cityshow 5 more

Code:

NCT05257473

Conditions

Becker Muscular Dystrophy

Muscular Dystrophies

Muscular Dystrophy in Children

Muscular Dystrophy, Becker

Eligibility Criteria

Sex: Male

Age: 6+

Healthy Volunteers: Not accepted

A Study to Evaluate the Safety and Clinical Activity of Intramuscular Doses of BB-301 Administered to Subjects With Oculopharyngeal Muscular Dystrophy With Dysphagia

Recruiting

PHASE1

PHASE2

Sponsor:

Benitec Biopharma, Inc.

Location:

New York

Code:

NCT06185673

Conditions

Oculopharyngeal Muscular Dystrophy

Eligibility Criteria

Sex: All

Age: 0 - 65

Healthy Volunteers: Not accepted

Interventions

BB-301: Dose escalation phase 1b cohort 1

BB-301: Dose escalation phase 1b cohort 2

BB-301: Dose escalation phase 1b cohort 3

BB-301: Dose expansion phase 2a